S. Panowski
mAbs · 2013
A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Whom S. Panowski trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Panowski overall
Papers from S. Panowski's perspective
Ordered by how strongly the researchers S. Panowski trusts endorse each paper. Same corpus, a different order for every researcher.
- Arming antibodies: prospects and challenges for immunoconjugates (Nature Biotechnology)
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
- Targeted cancer therapy: conferring specificity to cytotoxic drugs. (Accounts of Chemical Research)
- Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate (Clinical Cancer Research)
- Monoclonal antibody successes in the clinic (Nature Biotechnology)
- Characterization of Mammalian Selenoproteomes (Science)
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (Nature Biotechnology)
- A history of cancer chemotherapy. (Cancer Research)
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (Nature Biotechnology)
- An enhanced system for unnatural amino acid mutagenesis in E. coli. (Journal of Molecular Biology)
Their papers
- Site-specific antibody drug conjugates for cancer therapy (2013) — 623 citations